FDA Approves Gedatolisib for Advanced HR-Positive Breast Cancer

The U.S. Food and Drug Administration (FDA) approved the kinase inhibitor gedatolisib, marketed as Revtorpyk, for the treatment of hormone receptor (HR)-positive and HER2-negative breast cancer. This approval specifically targets patients whose disease has progressed despite endocrine therapy in the metastatic setting. Gedatolisib functions as a dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways, which are frequently dysregulated in HR-positive breast cancer and contribute to tumor growth and resistance to endocrine treatments.

The FDA's decision was based on findings from the Phase 3 trial, which demonstrated significant clinical benefit in patients treated with gedatolisib in combination with fulvestrant. Fulvestrant is a selective estrogen receptor degrader (SERD) commonly used in endocrine therapy for breast cancer. The trial results indicated an improvement in progression-free survival (PFS) for patients receiving the combination therapy compared to those receiving fulvestrant alone. Specific data regarding the magnitude of PFS improvement and overall survival benefits were key factors in the regulatory review process.

This approval offers a new therapeutic option for a patient population with limited choices after standard endocrine therapies have failed. The PI3K/mTOR pathway is a critical signaling network involved in cell growth, proliferation, and survival. Its aberrant activation is a common mechanism of resistance to endocrine therapy in HR-positive breast cancer. By inhibiting both PI3K and mTOR, gedatolisib aims to overcome this resistance and restore sensitivity to endocrine treatment. The drug's development represents a targeted approach to address specific molecular drivers of cancer progression.

Revtorpyk (gedatolisib) is administered orally, offering a convenient dosing schedule for patients. The FDA's review process involved a thorough evaluation of the drug's safety and efficacy profile, including data from clinical trials that enrolled a diverse patient population. The approval marks a significant advancement in the treatment landscape for advanced HR-positive, HER2-negative breast cancer, a subtype that accounts for a substantial proportion of all breast cancer cases. Further research is ongoing to explore gedatolisib's potential in other breast cancer subtypes and in earlier lines of therapy.